Trial Profile
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK4305 in Patients With Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 26 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 26 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.